One Broadway, 14th Floor
About Exonics Therapeutics
At Exonics Therapeutics, our mission is to permanently correct genetic mutations resulting in neuromuscular diseases like Duchenne muscular dystrophy. Duchenne is a devastating muscle disease in children, primarily boys, caused by the absence of dystrophin. Our approach utilizes gene editing technologies such as CRISPR/Cas9 to correct a majority of the genetic mutations in Duchenne, and enable dystrophin production.
CEO – John Ripple
8 articles with Exonics Therapeutics
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exonics Therapeutics
Deal will accelerate drug development for Duchenne muscular dystrophy, a rare disease that affects 300,000 boys and young men worldwide
Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics
Vertex Pharmaceuticals Incorporated announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1 by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics.
Researchers at the University of Texas Southwestern Medical Center used CRISPR gene editing to treat Duchenne muscular dystrophy (DMD) in dogs. Their work was published in the journal Science.
Since 2013, Dr. Perlmutter has served as executive vice president of Merck and president of Merck Research Laboratories.
The cash will allow the company to hire scientists to conduct preclinical research into a potential treatment for DMD.
Exonics Therapeutics closed on a $40M Series A financing which was led by The Column Group.